|
1
|
Tang S, Zhao C, Zhu X. Engineering Escherichia coli-Derived Nanoparticles for Vaccine Development. Vaccines (Basel) 2024; 12:1287. [PMID: 39591189 PMCID: PMC11598912 DOI: 10.3390/vaccines12111287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 11/13/2024] [Accepted: 11/13/2024] [Indexed: 11/28/2024] Open
Abstract
The development of effective vaccines necessitates a delicate balance between maximizing immunogenicity and minimizing safety concerns. Subunit vaccines, while generally considered safe, often fail to elicit robust and durable immune responses. Nanotechnology presents a promising approach to address this dilemma, enabling subunit antigens to mimic critical aspects of native pathogens, such as nanoscale dimensions, geometry, and highly repetitive antigen display. Various expression systems, including Escherichia coli (E. coli), yeast, baculovirus/insect cells, and Chinese hamster ovary (CHO) cells, have been explored for the production of nanoparticle vaccines. Among these, E. coli stands out due to its cost-effectiveness, scalability, rapid production cycle, and high yields. However, the E. coli manufacturing platform faces challenges related to its unfavorable redox environment for disulfide bond formation, lack of post-translational modifications, and difficulties in achieving proper protein folding. This review focuses on molecular and protein engineering strategies to enhance protein solubility in E. coli and facilitate the in vitro reassembly of virus-like particles (VLPs). We also discuss approaches for antigen display on nanocarrier surfaces and methods to stabilize these carriers. These bioengineering approaches, in combination with advanced nanocarrier design, hold significant potential for developing highly effective and affordable E. coli-derived nanovaccines, paving the way for improved protection against a wide range of infectious diseases.
Collapse
Affiliation(s)
- Shubing Tang
- Shanghai Reinovax Biologics Co., Ltd., Pudong New District, Shanghai 200135, China;
| | - Chen Zhao
- Shanghai Public Health Clinical Center, Fudan University, Shanghai 201058, China
| | - Xianchao Zhu
- Shanghai Reinovax Biologics Co., Ltd., Pudong New District, Shanghai 200135, China;
| |
Collapse
|
|
2
|
Lemos-Pérez G, Barrese-Pérez Y, Chacón-Quintero Y, Uranga-Piña R, Avila-Albuerne Y, Figueroa-García I, Calderín-Marín O, Gómez-Vázquez MM, Piñera-Martínez M, Chávez-Valdés S, Martínez-Rosales R, Ávila-Díaz L, Vázquez-Arteaga A, González-Formental H, Freyre-Corrales G, Coizeau-Rodríguez E, Limonta-Fernández M, Ayala-Avila M, Martínez-Díaz E, Pimentel-Vazquez E, Guillen G. Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial. Vaccines (Basel) 2024; 12:1001. [PMID: 39340031 PMCID: PMC11435458 DOI: 10.3390/vaccines12091001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Revised: 07/23/2024] [Accepted: 08/02/2024] [Indexed: 09/30/2024] Open
Abstract
A phase 1-2, prospective, multicenter, randomized, open-label clinical trial (Code RPCEC00000382), with parallel groups, involving 1161 participants, was designed to assess the safety and immunogenicity of two Cuban COVID-19 vaccines (Mambisa and Abdala) in boosting COVID-19 immunity of convalescent adults after receiving one dose of either vaccine. The main safety outcome was severe vaccination adverse events occurring in <5% of vaccinees. Main immunogenicity success endpoints were a ≥4-fold anti-RBD IgG seroconversion or a ≥20% increase in ACE2-RBD inhibitory antibodies in >55% of vaccinees in Phase 1 and >70% in Phase 2. Neutralizing antibody titers against SARS-CoV-2 variants were evaluated. Both vaccines were safe-no deaths or severe adverse events occurred. Mild intensity adverse events were the most frequent (>73%); headaches predominated for both vaccines. Phase 1 responders were 83.3% (p = 0.0018) for Abdala. Mambisa showed similar results. Phase 2 responders were 88.6% for Abdala (p < 0.0001) and 74.2% for Mambisa (p = 0.0412). In both phases, anti-RBD IgG titers, inhibition percentages and neutralizing antibody titers increased significantly after the booster dose. Both vaccines were safe and their immunogenicity surpassed the study endpoints.
Collapse
Affiliation(s)
- Gilda Lemos-Pérez
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Yinet Barrese-Pérez
- National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba; (Y.B.-P.); (R.U.-P.); (Y.A.-A.)
| | - Yahima Chacón-Quintero
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Rolando Uranga-Piña
- National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba; (Y.B.-P.); (R.U.-P.); (Y.A.-A.)
| | - Yisel Avila-Albuerne
- National Coordinating Center for Clinical Trials (CENCEC), La Habana 11300, Cuba; (Y.B.-P.); (R.U.-P.); (Y.A.-A.)
| | | | - Osaida Calderín-Marín
- Manuel Ascunce Domenech Provincial Clinical-Surgical Teaching Hospital, Camagüey 70100, Cuba;
| | | | | | - Sheila Chávez-Valdés
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Ricardo Martínez-Rosales
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Lismary Ávila-Díaz
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Amalia Vázquez-Arteaga
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Hany González-Formental
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Giselle Freyre-Corrales
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Edelgis Coizeau-Rodríguez
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Miladys Limonta-Fernández
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | - Marta Ayala-Avila
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
| | | | | | - Gerardo Guillen
- Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, La Habana 10600, Cuba; (Y.C.-Q.); (S.C.-V.); (R.M.-R.); (L.Á.-D.); (A.V.-A.); (H.G.-F.); (G.F.-C.); (E.C.-R.); (M.L.-F.); (M.A.-A.)
- Latin American School of Medicine (ELAM), La Habana 19108, Cuba
| |
Collapse
|
|
3
|
Aguilar JC, Akbar SMF, Al-Mahtab M, Khan MSI, Guzman CA, Fernandez G, Aguiar JA, Michel ML, Bourgine M, Marrero MA, Trittel S, Ebensen T, Riese P, Le Grand R, Herate C, Mauras A, Yoshida O, Hiasa Y, Penton E, Guillen GE. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepatogastroenterol 2024; 14:221-237. [PMID: 39802853 PMCID: PMC11714097 DOI: 10.5005/jp-journals-10018-1457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Accepted: 11/28/2024] [Indexed: 01/16/2025] Open
Abstract
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation. How to cite this article Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
Collapse
Affiliation(s)
- Julio C Aguilar
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Sheikh MF Akbar
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Mamun Al-Mahtab
- Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
| | - Md Sakirul I Khan
- Department of Research Center for Global and Local Infectious Diseases, Oita University, Oita, Japan
| | - Carlos A Guzman
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Guillermo Fernandez
- Department of Gastroenterology, Abel Santamaría Hospital, Pinar del Rio, Cuba
| | - Jorge A Aguiar
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Marie-Louise Michel
- Laboratory of Hepatitis B Virus Pathogenesis, Institut Pasteur, Paris, France
| | - Maryline Bourgine
- Department of Institut Pasteur-TheraVectys Joint Lab, Institut Pasteur Paris, France
| | - Maria A Marrero
- Department of Clinical Trials, National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba
| | - Stephanie Trittel
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Thomas Ebensen
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Peggy Riese
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Roger Le Grand
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Cecile Herate
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Aurelie Mauras
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Osamu Yoshida
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Eduardo Penton
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Gerardo E Guillen
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| |
Collapse
|
|
4
|
Lobaina Y, Chen R, Suzarte E, Ai P, Huerta V, Musacchio A, Silva R, Tan C, Martín A, Lazo L, Guillén-Nieto G, Yang K, Perera Y, Hermida L. The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality. Viruses 2024; 16:418. [PMID: 38543783 PMCID: PMC10976088 DOI: 10.3390/v16030418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 05/23/2024] Open
Abstract
Despite the rapid development of vaccines against COVID-19, they have important limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal immunity. The present study proposes a potential component for a new generation of vaccines. The recombinant nucleocapsid (N) protein from the SARS-CoV-2 Delta variant was combined with the ODN-39M, a synthetic 39 mer unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), used as an adjuvant. The evaluation of its immunogenicity in Balb/C mice revealed that only administration by intranasal route induced a systemic cross-reactive, cell-mediated immunity (CMI). In turn, this combination was able to induce anti-N IgA in the lungs, which, along with the specific IgG in sera and CMI in the spleen, was cross-reactive against the nucleocapsid protein of SARS-CoV-1. Furthermore, the nasal administration of the N + ODN-39M preparation, combined with RBD Delta protein, enhanced the local and systemic immune response against RBD, with a neutralizing capacity. Results make the N + ODN-39M preparation a suitable component for a future intranasal vaccine with broader functionality against Sarbecoviruses.
Collapse
Affiliation(s)
- Yadira Lobaina
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China
| | - Rong Chen
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China
| | - Edith Suzarte
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Panchao Ai
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China
| | - Vivian Huerta
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Alexis Musacchio
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Ricardo Silva
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China
| | - Changyuan Tan
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China
| | - Alejandro Martín
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Laura Lazo
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Gerardo Guillén-Nieto
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Ke Yang
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China
| | - Yasser Perera
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China
- CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba; (E.S.); (A.M.); (L.L.); (G.G.-N.)
| | - Lisset Hermida
- Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China; (Y.L.); (R.C.); (P.A.); (V.H.); (A.M.); (R.S.); (C.T.)
- Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China
- BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China
| |
Collapse
|
|
5
|
Aguiar Santiago JA, Marrero Miragaya MA, Figueroa Oliva DA, Aguilar Juanes A, Idavoy Corona A, Martínez Fernández S, Morán Bertot I, Rodríguez Hernández M, Canales López E, Hernández Esteves I, Silva Girado JA, Estrada Vázquez RC, Gell Cuesta O, Mendoza-Marí Y, Valdés Prado I, Rodríguez Ibarra C, Palenzuela Gardon DO, Pentón Arias E, Guillén Nieto G, Aguilar Rubido JC. Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac. DNA Cell Biol 2024; 43:95-102. [PMID: 38118108 DOI: 10.1089/dna.2023.0283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2023] Open
Abstract
HeberNasvac, a therapeutic vaccine for chronic hepatitis B, is able to safely stimulate multiple Toll-like receptors, increasing antigen presentation in vitro and in a phase II clinical trial (Profira) in elderly volunteers who were household contacts of respiratory infection patients. Thus, a new indication as a postexposure prophylaxis or early therapy for respiratory infections has been proposed. In this study, we evaluated the expression of several interferon-stimulated genes (ISGs) after mucosal administration of HeberNasvac and compared this effect with the nasal delivery of interferon alpha 2b (Nasalferon). Molecular studies of blood samples of 50 subjects from the Profira clinical trial who were locally treated with HeberNasvac or Nasalferon and concurrent untreated individuals were compared based on their relative mRNA expression of OAS1, ISG15, ISG20, STAT1, STAT3, and DRB1-HLA II genes. In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ivis Morán Bertot
- Plant Molecular Biology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | | - Eduardo Canales López
- Plant Genomic Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | | - José Angel Silva Girado
- Olinonucleotide Synthesis Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | | - Omar Gell Cuesta
- Olinonucleotide Synthesis Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Yssel Mendoza-Marí
- Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Iris Valdés Prado
- Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | | | | - Eduardo Pentón Arias
- Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Gerardo Guillén Nieto
- Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | |
Collapse
|
|
6
|
Mahmood F, Xu R, Awan MUN, Song Y, Han Q, Xia X, Wei J, Xu J, Peng J, Zhang J. HBV Vaccines: Advances and Development. Vaccines (Basel) 2023; 11:1862. [PMID: 38140265 PMCID: PMC10747071 DOI: 10.3390/vaccines11121862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 12/09/2023] [Accepted: 12/12/2023] [Indexed: 12/24/2023] Open
Abstract
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as a result of the introduction of universal HBV vaccination programs. The first hepatitis B vaccine approved was developed by purifying the hepatitis B surface antigen (HBsAg) from the plasma of asymptomatic HBsAg carriers. Subsequently, recombinant DNA technology led to the development of the recombinant hepatitis B vaccine. Although there are already several licensed vaccines available for HBV infection, continuous research is essential to develop even more effective vaccines. Prophylactic hepatitis B vaccination has been important in the prevention of hepatitis B because it has effectively produced protective immunity against hepatitis B viral infection. Prophylactic vaccines only need to provoke neutralizing antibodies directed against the HBV envelop proteins, whereas therapeutic vaccines are most likely needed to induce a comprehensive T cell response and thus, should include other HBV antigens, such as HBV core and polymerase. The existing vaccines have proven to be highly effective in preventing HBV infection, but ongoing research aims to improve their efficacy, duration of protection, and accessibility. The routine administration of the HBV vaccine is safe and well-tolerated worldwide. The purpose of this type of immunization is to trigger an immunological response in the host, which will halt HBV replication. The clinical efficacy and safety of the HBV vaccine are affected by a number of immunological and clinical factors. However, this success is now in jeopardy due to the breakthrough infections caused by HBV variants with mutations in the S gene, high viral loads, and virus-induced immunosuppression. In this review, we describe various types of available HBV vaccines, along with the recent progress in the ongoing battle to develop new vaccines against HBV.
Collapse
Affiliation(s)
- Faisal Mahmood
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
- Central Laboratory, Liver Disease Research Center and Department of Infectious Disease, The Affiliated Hospital of Yunnan University, Kunming 650021, China;
| | - Ruixian Xu
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
| | - Maher Un Nisa Awan
- Department of Neurology, The Affiliated Hospital of Yunnan University, No. 176 Qingnian Road, Kunming 650021, China; (M.U.N.A.); (J.X.)
| | - Yuzhu Song
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
| | - Qinqin Han
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
| | - Xueshan Xia
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
| | - Jia Wei
- Central Laboratory, Liver Disease Research Center and Department of Infectious Disease, The Affiliated Hospital of Yunnan University, Kunming 650021, China;
| | - Jun Xu
- Department of Neurology, The Affiliated Hospital of Yunnan University, No. 176 Qingnian Road, Kunming 650021, China; (M.U.N.A.); (J.X.)
| | - Juan Peng
- The Obstetrical Department, The First People’s Hospital of Yunnan Province, Kunming 650032, China;
| | - Jinyang Zhang
- Molecular Medicine Research Centre of Yunnan Province, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; (F.M.); (R.X.); (Y.S.); (Q.H.); (X.X.)
| |
Collapse
|